Drugs that contain Fenofibrate
1. List of Antara (micronized) drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8026281 | LUPIN | Treating metabolic syndrome with fenofibrate |
Apr, 2025
(1 year, 10 months from now) | |
| US9314447 | LUPIN | Reduced dose pharmaceutical compositions of fenofibrate |
May, 2033
(9 years from now) | |
Market Authorisation Date: 30 November, 2004
Treatment: Treating severe hypertriglyceridemia; Treating primary hypercholesterolemia and mixed dyslipidemia
Dosage: CAPSULE;ORAL
2. List of Fenoglide drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8124125 | SALIX | Solid dosage form comprising a fibrate |
Oct, 2024
(1 year, 3 months from now) | |
| US8481078 | SALIX | Solid dosage form comprising a fibrate |
Oct, 2024
(1 year, 3 months from now) | |
| US9173847 | SALIX | Tablet comprising a fibrate |
Oct, 2024
(1 year, 3 months from now) | |
| US7658944 | SALIX | Solid dosage form comprising a fibrate |
Dec, 2024
(1 year, 6 months from now) | |
Market Authorisation Date: 10 August, 2007
Treatment: For reducing total cholesterol (total-c), ldl-c, apo-lipoprotein b, or total triglycerides, and treating hypertriglyceridemia; Use of fenofibrate for reducing elevated total cholesterol (total-c), ldl...
Dosage: TABLET;ORAL
3. List of Tricor drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7320802 | ABBVIE | Methods of treatment using nanoparticulate fenofibrate compositions |
Feb, 2023
(3 months ago) | |
| US7276249 | ABBVIE | Nanoparticulate fibrate formulations |
Feb, 2023
(3 months ago) | |
Market Authorisation Date: 05 November, 2004
Treatment: Adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hype...
Dosage: TABLET;ORAL
TRICOR family patents
94
United States
24
Japan
17
European Union
14
Canada
14
Australia
9
Austria
8
Germany
6
Spain
4
Korea, Republic of
4
Denmark
4
Argentina
3
Taiwan
3
China
3
Portugal
3
Cyprus
2
Uruguay
2
Mexico
2
New Zealand
2
EA
2
Norway
1
Brazil
1
Morocco
1
Malaysia
1
South Africa
1
Tunisia
1
Singapore
1
Israel
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic